Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

NCT06784648 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma Metastatic
Melanoma of Skin
Melanoma BRAF V600E/K Mutated
Melanoma Recurrent
Melanoma Stage III or IV
Melanoma
Melanoma Negative for bRAF
Melanoma Negative for nRAS
Melanomas
Uveal Melanoma, Metastatic

Interventions

BIOLOGICAL: pembrolizumab (KEYTRUDA®)
BIOLOGICAL: BI-1607
BIOLOGICAL: Ipilimumab (YervoyTM, 50 mg/10 mL solution)

Sponsor

BioInvent International AB

Collaborators

[object Object]